SMC approves bimekizumab for hidradenitis suppurativa treatment
7th April 2025 Uncategorised 0
The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional systemic therapies. This approval makes Scotland the first country in the UK to offer bimekizumab for HS patients. HS is a chronic inflammatory skin condition affecting 0.77% of the UK population. […]
More: SMC approves bimekizumab for hidradenitis suppurativa treatment
Source: News